HIGHLIGHTS
- who: Jill I. Olydam from the the LudwigMaximilian University of have published the Article: EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab, in the Journal: (JOURNAL)
- what: This study shows that the use of a biomarker signature (p-EASI) reflects disease severity in patients with AD treated with tralokinumab in a clinical trial setting.
- future: Research is needed to correlate clinical important outcome measures such as EASI50/EASI75.
SUMMARY
Published points using the formula: b0t - b1t log (TARC) - b2t IL-22 - b3t sIL . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.